Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.

Xu, Hua; Sun, Yin; Huang, Chi-Ping; You, Bosen; Ye, Dingwei; Chang, Chawnshang

Xu, Hua; Sun, Yin; Huang, Chi-Ping; You, Bosen; Ye, Dingwei; Chang, Chawnshang.

Afiliação

Xu H; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Sun Y; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Huang CP; George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14646, USA.
You B; The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14646, USA.
Ye D; George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, University of Rochester Medical Center, Rochester, NY 14646, USA.
Chang C; The Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14646, USA.

Cancers (Basel) ; 12(4)2020 Mar 30.

Article em En | MEDLINE | ID: mdl-32235588

Palavras-chave

ABT263; ARv7; Enzalutamide; androgen receptor; prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google